Bloodwork markers are the instrument panel for enhanced physiology. Quarterly monitoring prevents the three failure modes that end cycles early: hepatotoxicity from methylated orals, polycythemia from testosterone or trenbolone, and metabolic syndrome from ignoring lipid dysregulation. This protocol covers 22 markers across five systems, organized by intervention threshold and monitoring cadence for men running androgens year-round or in extended cycles beyond 16 weeks.
Mechanism
Anabolic androgenic steroids and selective androgen receptor modulators exert systemic effects beyond skeletal muscle. Androgen receptor activation in hepatocytes alters lipid metabolism, suppressing hepatic lipase and increasing LDL receptor downregulation. Erythropoietin upregulation from androgen signaling increases red blood cell mass, useful for endurance but pathological above hematocrit of 54%. Methylated C17-alpha-alkylated compounds resist first-pass hepatic metabolism, creating oxidative stress measurable through ALT, AST, and GGT elevation within 3-6 weeks at doses above 30 mg daily.
The hypothalamic-pituitary-gonadal axis suppression from exogenous androgens eliminates endogenous testosterone and LH production within 2-4 weeks, measurable through LH below 0.5 IU/L and total testosterone either supraphysiological (on cycle) or sub-100 ng/dL (post-cycle before recovery). Aromatase enzyme conversion of testosterone to estradiol occurs primarily in adipose tissue, with individual variation creating estradiol levels from 10-80 pg/mL on identical testosterone doses. Free testosterone, calculated from total testosterone and SHBG using mass action equations, determines bioavailable androgen activity more accurately than total levels.
Renal filtration capacity, assessed through creatinine and eGFR, declines from increased muscle mass (higher creatinine production) and from direct nephrotoxicity of certain compounds. Cystatin C provides a non-muscle-mass-dependent filtration marker. Fasting insulin and glucose reveal insulin resistance development, common with high-dose growth hormone, high-carbohydrate refeeds, and certain androgens like oxymetholone.
Protocol
Order comprehensive panels quarterly (12-week intervals) when running continuous protocols. Order pre-cycle baseline, week-4 on-cycle, and 6-week post-cycle when cycling. Use LabCorp, Quest, or direct-to-consumer services like Marek Health or PrivateMDLabs. Always draw fasted (10-12 hours), between 0700-0900 hours to control for circadian variation, 48 hours after last training session to avoid acute inflammation markers.
Lipid Panel (5 markers): Total cholesterol, LDL-C, HDL-C, triglycerides, ApoB. Intervention threshold: HDL below 35 mg/dL, LDL above 160 mg/dL, ApoB above 100 mg/dL, triglycerides above 200 mg/dL. Mitigation: 4 g/day EPA+DHA fish oil, 2 g/day niacin (flush or extended-release), 10 mg/day ezetimibe, or 10-20 mg/day rosuvastatin for LDL above 180 mg/dL. Statin protocols require CoQ10 supplementation at 200 mg daily.
Hepatic Function (3 markers): ALT, AST, GGT. Intervention threshold: ALT or AST above 80 IU/L (2x upper normal), GGT above 100 IU/L. Immediately discontinue methylated orals. Add 1200 mg/day TUDCA, 1800 mg/day NAC, and 600 mg/day alpha-lipoic acid. Recheck at 2 weeks. Persistent elevation above 150 IU/L requires imaging to rule out steatosis or cholestasis.
Renal Function (3 markers): Creatinine, eGFR, cystatin C. Baseline creatinine rises 0.2-0.4 mg/dL per 20 lb lean mass gain. Intervention threshold: eGFR below 60 mL/min/1.73m², cystatin C above 1.2 mg/L. Increase water intake to 1 gallon daily minimum, reduce protein below 1.2 g/lb if eGFR dropping, discontinue nephrotoxic compounds (high-dose boldenone, excessive diuretics).
Hematological (4 markers): Hemoglobin, hematocrit, RBC count, platelet count. Intervention threshold: hematocrit above 52%, hemoglobin above 18 g/dL. Therapeutic phlebotomy (donate 1 unit whole blood) drops hematocrit 3-4 points. Repeat every 8-12 weeks if needed. Grapefruit seed extract 500 mg twice daily and naringin 500 mg daily reduce hematocrit 2-3 points over 4 weeks through decreased erythropoiesis. Platelet counts below 150 k/μL warrant evaluation for bone marrow suppression from certain SARMs.
Hormonal (5 markers): Total testosterone, free testosterone, estradiol (sensitive LC/MS), LH, SHBG. On-cycle testosterone should match predicted levels: 150 mg/week produces roughly 1200-1500 ng/dL trough, 500 mg/week produces 3000-4000 ng/dL. Estradiol target 20-40 pg/mL for most men; symptoms matter more than number. SHBG typically drops 30-50% on cycle. LH below 0.1 IU/L confirms full suppression. Post-cycle, LH recovery precedes testosterone recovery by 2-4 weeks. Persistent LH below 1.5 IU/L at 8 weeks post-cycle suggests incomplete HPG axis recovery, indicating need for HCG or SERM intervention.
Metabolic (2 markers): Fasting glucose, fasting insulin. Calculate HOMA-IR: (glucose mg/dL × insulin μIU/mL) / 405. Intervention threshold: fasting glucose above 105 mg/dL, fasting insulin above 10 μIU/mL, HOMA-IR above 2.0. Add 2000 mg/day metformin, 200 mcg chromium picolinate, 600 mg alpha-lipoic acid twice daily. Reduce growth hormone dose if above 3 IU/day.
Monitoring
Establish individual baseline across three pre-cycle draws spaced 4 weeks apart. Genetic variation and training status create 20-30% inter-individual variation in baseline markers. A powerlifter’s baseline creatinine of 1.4 mg/dL is normal; the same number in a 170 lb runner suggests renal impairment.
Week-4 on-cycle bloodwork captures acute response to androgens before adaptation. Lipid changes plateau by week 6-8. Hepatic enzymes from methylated orals peak week 4-6. Hematocrit rises linearly 1-2% per month on testosterone until plateau at week 12-16. Estradiol achieves steady-state by week 3-4 on testosterone esters with half-lives of 4-7 days.
Mid-cycle checks at week 8-10 on extended protocols confirm stability or catch late-developing issues. Triglycerides can spike mid-cycle if diet shifts toward higher carbohydrate intake. GGT may rise as a delayed hepatic stress marker even after ALT/AST normalize.
Post-cycle monitoring determines recovery timeline. Check at week 4, 6, and 10 post-cycle. Testosterone recovery to 300 ng/dL by week 6 predicts full recovery to baseline by week 10-12. Persistent suppression beyond week 12 may indicate primary hypogonadism or inadequate PCT. Estradiol often drops below baseline post-cycle if aromatase inhibitors were used, causing low-E2 symptoms (joint pain, low libido, mood issues) despite adequate testosterone.
Add thyroid panel (TSH, free T3, free T4, reverse T3) if using growth hormone above 4 IU/day or experiencing persistent fatigue despite normal testosterone and estradiol. TSH above 3.0 mIU/L or reverse T3 above 20 ng/dL suggests thyroid downregulation. Add prostate-specific antigen (PSA) annually after age 35 or if using DHT derivatives; intervention threshold is PSA above 2.5 ng/mL or year-over-year increase above 0.75 ng/mL. Add cardiovascular markers (hs-CRP, homocysteine, Lp(a)) annually for men over 35 or with family history of early cardiovascular disease.
Risks and Mitigation
Lipid dysregulation is universal on androgens, particularly 19-nortestosterone compounds and stanozolol. HDL drops 40-60% on trenbolone, creating a months-long atherogenic lipid profile. Mitigation: limit 19-nor compounds to 12-16 week blocks, use time-on equals time-off cycling, maintain systolic blood pressure below 130 mmHg, add ezetimibe or low-dose statin if LDL exceeds 160 mg/dL despite fish oil and niacin.
Hepatotoxicity from methylated orals (superdrol, anavar, anadrol, epistane) is dose and duration dependent. Six weeks at 20 mg/day superdrol produces ALT above 100 IU/L in 70% of users. Mitigation: limit methylated compounds to 4-6 weeks, doses below 50 mg/day for milder compounds, never stack multiple hepatotoxic compounds, front-load TUDCA and NAC from day one rather than waiting for enzyme elevation.
Polycythemia above hematocrit 54% increases blood viscosity and thrombotic risk. Risk scales with age and additional cardiovascular risk factors. Mitigation: therapeutic phlebotomy every 8-12 weeks as needed, maintain hydration above 1 gallon daily, consider reducing testosterone dose from 500 mg/week to 300 mg/week if hematocrit repeatedly exceeds 54% despite phlebotomy, avoid training in extreme heat.
Insulin resistance develops insidiously, particularly with growth hormone above 4 IU/day or high-dose androgens combined with caloric surplus. Fasting glucose creeping from 85 mg/dL to 105 mg/dL over 6 months predicts future diabetes risk. Mitigation: metformin 1000-2000 mg/day, berberine 500 mg three times daily as alternative, maintain aerobic conditioning (Zone 2 cardio 150 min/week), avoid excessive fructose intake.
Comparisons
Standard hormone panels from general practitioners capture total testosterone, basic metabolic panel, and lipid panel but miss free testosterone, sensitive estradiol (using LC/MS instead of immunoassay), and hematocrit. The immunoassay estradiol method used in standard panels overestimates by 20-40% in men, creating false high readings. Insist on LC/MS methodology or order through specialty labs.
Female hormone panels include progesterone, FSH at specific cycle days, and different estradiol reference ranges. These panels are useless for men on androgens. Never accept a “hormone panel” without confirming it includes male-specific markers.
Direct-to-consumer panels range from $150-400 depending on marker breadth. Marek Health and PrivateMDLabs offer pre-configured male hormone enhancement panels including sensitive estradiol, full lipid panel, hepatic and renal markers. Insurance-billed panels through physician orders run $50-150 after insurance but often exclude sensitive estradiol and require diagnosis code justification for comprehensive testing. Cash-pay labs avoid medical record documentation.
Annual executive physical panels include extensive cardiac imaging (CT angiography, carotid ultrasound) and cancer screening but often miss weekly/monthly hormonal fluctuations. These complement but don’t replace quarterly cycle-specific monitoring. The $3000 executive panel catching early atherosclerosis is worthless if you miss the week-4 ALT spike that becomes acute liver injury by week 8.
Common Mistakes
Testing non-fasted or at inconsistent times creates false variation. Triglycerides swing 100+ mg/dL based on meal timing. Testosterone peaks at 0800 and drops 30% by 1600. Always test same conditions: fasted, morning, 48 hours post-training.
Chasing estradiol numbers instead of symptoms. Men feel optimal anywhere from 15-60 pg/mL depending on testosterone levels and individual sensitivity. Crashing estradiol to single digits with excessive AI creates worse side effects than the high estradiol it was meant to prevent. Adjust AI dose based on nipple sensitivity, water retention, and libido, not based on hitting an arbitrary number.
Ignoring lipids because “I feel fine.” Atherosclerosis is asymptomatic for years until it causes myocardial infarction. HDL of 25 mg/dL and LDL of 200 mg/dL on 600 mg trenbolone/week feels identical to perfect lipids until the sudden cardiac event. This is why intervention thresholds exist independent of symptoms.
Testing too early post-injection. Testosterone levels spike 24-48 hours after injection and return to steady-state trough before next injection. Testing 24 hours after 500 mg injection shows 6000 ng/dL; testing at trough shows 3000 ng/dL. Both are the same protocol, different timing. Always test at trough (morning before next injection) for accurate steady-state levels.
Skipping post-cycle monitoring because testosterone “feels recovered.” Subjective libido and energy return before full HPG axis recovery. Testing confirms LH and FSH recovery, ensuring fertility potential returns and preventing prolonged hypogonadism misdiagnosed as “permanent shutdown.”
Bottom Line
- Quarter bloodwork at 12-week intervals minimum: lipid panel, hepatic function (ALT/AST/GGT), renal function (creatinine/eGFR/cystatin C), CBC with differential, full male hormone panel with sensitive estradiol LC/MS, fasting glucose and insulin
- Intervention thresholds: HDL below 35 mg/dL, hematocrit above 52%, ALT above 80 IU/L, fasting glucose above 105 mg/dL, eGFR below 60 mL/min/1.73m²
- Test fasted, 0700-0900 hours, 48 hours post-training, at trough before next injection
- Lipid dysregulation, hepatotoxicity, and polycythemia are dose-dependent and reversible with protocol adjustment or ancillary intervention
- Cash-pay specialty labs provide comprehensive male panels with sensitive estradiol for $200-300; establish baseline with three pre-cycle draws spaced 4 weeks apart